Skip to main content
. 2020 Sep 16;21(1):1115. doi: 10.4102/sajhivmed.v21i1.1115

TABLE 15.

Recommended second-line regimen in patients who have failed a first-line regimen of two nucleoside reverse transcriptase inhibitors + dolutegravir.

Failing first-line regimen Advised second-line regimen
Two NRTIs + DTG Only switch to second-line regimen if the resistance test shows DTG resistance and the second line should be two NRTIs (selected based on resistance test) + DRV/r

DTG, dolutegravir; NRTI, nucleoside reverse transcriptase inhibitor; DRV, darunavir/ritonavir.